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Left ventricular assist device (LVAD) pump thrombosis is a well-known
complication of LVAD placement. Elevated lactate dehydrogenase (LDH) has
classically been the first objective marker of pump thrombosis. In this case, we
present a patient found to have normal serum LDH values but was ultimately found
to have significant pump thrombosis.
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Introduction
Pump thrombosis is a well-known complication of left ventricular assist device
(LVAD). Elevated lactate dehydrogenase (LDH) has classically been the first and
most consistent objective marker of this condition. In this case, we present a
patient with completely normal serum LDH values who was ultimately found to
have pump thrombosis.
Case Presentation
A 64-year-old gentleman with a Heartware HVAD left ventricular assist device
(LVAD) initially presented to an outside emergency department with progressive
fatigue, melena for one week, along with an abrupt drop in the flow rate noted on
his device’s controller. His LVAD was placed two years prior to presentation in the
setting of chronic systolic heart failure secondary to ischemic cardiomyopathy.
The patient’s home anticoagulation regimen consisted of aspirin 81 mg daily and
warfarin titrated to a target INR of 1.5-1.8. In the year and a half since
implantation, he experienced multiple episodes of gastrointestinal bleeding and
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underwent multiple endoscopic procedures, including eight colonoscopies. The
procedures were unrevealing with no overt source of bleeding identified. While he
had felt fatigued over one week, he acutely felt worse on the day of presentation.
Furthermore, the patient noticed that the flow on his LVAD controller dropped from
4.5 L/min to less than 1 L/min. On review of systems, the patient mentioned he
had recurrence of melena over the last week. Subsequent interrogation of his
LVAD in the emergency room confirmed flows less than 1 L/min as well as absent
pulsatility on the flow waveform. He was found to be anemic and two units of
packed red blood cells along with 1 L of intravenous fluids was administered. A
continuous dopamine infusion was started for hypotension. The patient was
transferred to our institution for further care.
On arrival, the patient was in mixed cardiogenic and hypovolemic shock in the
setting of gastrointestinal bleeding. He was afebrile with a heart rate of 70
beats/min and a blood pressure of 92/75 mmHg. Laboratory data revealed a
hemoglobin of 6.7 g/dL with a hematocrit of 21.1%, platelet count of 254 k/µL, INR
of 2.0, serum creatinine of 1.79 mg/dL (baseline of 0.7 mg/dL), serum lactate
dehydrogenase (LDH) of 195 U/L (institutional reference range: 116-250 U/L), and
plasma free hemoglobin (pfHb) less than 3 mg/dL. LDH was checked repeatedly,
and remained within normal limits.
Over next several days, the patient became anuric with worsening serum
creatinine. He was referred for right heart catheterization to assess intracardiac
hemodynamics. Elevated right and left-sided filling pressures were seen with a
right atrial pressure of 20 mmHg, a pulmonary artery pressure of 74/29 mmHg
(mean 46 mmHg), and a pulmonary capillary wedge pressure of 27 mmHg. Mixed
venous oxygen saturation was 43%. Transthoracic echocardiography
demonstrated an ejection fraction of 20-30% with moderate to severe hypokinesis
of the left ventricle. His aortic valve opened with each beat.
Despite adequate volume resuscitation, including blood products, and the
escalation to three vasopressors, the patient’s LVAD flows remained low at about
2 L/min. We attempted to increase the pump speed to 3000 revolutions per
minute (rpms) but this did not result in a flow increase. Despite a normal hemolytic
work-up, our suspicion for pump thrombosis remained high. Cardiothoracic
surgery was consulted and the patient was taken to the operating room for LVAD
exchange. The hardware was found to have complete inflow and outflow
thrombus occlusion as well as thrombus within the left ventricle (Figure 1).
Figure 2 demonstrates the changes in intracardiac hemodynamics prior to and
shortly after pump exchange. Right atrial pressures decreased from an average of
22 mmHg for the 14 hours prior to surgery to 16 mmHg in the 19 hours after
surgery. Similarly, pulmonary artery systolic pressures ranged from 84-104 mmHg
preoperatively and improved to a range of 49-68 mmHg after pump exchange.
LVAD flows improved and the patient was able to be weaned off of all
vasopressors. Figure 3 demonstrates the normalization of his serum creatinine as
his urine output increased and acute kidney injury resolved. The red arrow
indicates the pump exchange.
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Figure 1: Inflow cannula demonstrating complete thrombosis.

Pump
exchange
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The patient’s hospital course was complicated by sustained ventricular tachycardia
requiring defibrillation as well as postoperative respiratory insufficiency with a left
pleural effusion requiring decortication. His gastrointestinal bleeding resolved
without intervention. He was later transplanted with no complications.

Discussion
The use of left ventricular assist devices (LVADs) is increasing in the management
of refractory end-stage heart failure1-2. As LVAD technology improves, there has
been a reduction in adverse events; however, pump thrombosis remains a lifethreatening complication3-4. The advantages of continuous flow LVADs are the
lower incidence of bleeding complications as well as the reduced rates of infection
when compared to pulsatile flow LVADs. Unfortunately, the challenges of pump
thrombosis, gastrointestinal bleeding, and aortic insufficiency persist3-4. In a
multicenter study, Starling et al. documented an increase in the rate of device
thrombosis in patients receiving the HeartMate II LVAD when compared to the preapproval clinical trials. In the last two years of the study, their group found that the
occurrence of pump thrombosis increased from 2.2% to 8.4% at three months
post-implantation10. Multiple other studies cite rates of confirmed pump
thrombosis between 0.9-14%3-12. Early detection and a high index of suspicion for
these complications are critical, as thromboembolic events and pump thrombosis
carry significant morbidity and mortality3,9-10.
Pump thrombosis is defined as clot within the flow path in any portion of the LVAD
device and should be suspected with clinical signs of heart failure, abnormal pump
parameters (such as sustained power spikes), elevated LDH, or clinical signs or
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symptoms of hemolysis 5, 11-12. The rise in LDH usually precedes a pump
thrombosis event, and routine monitoring is indicated to allow for early recognition
of possible pump thrombosis3. Cowger et al. have shown that an elevated LDH
was associated with increased adverse events in LVAD patients, and LDH
monitoring parameters may allow for earlier detection of pump thrombosis. In the
setting of hemolysis, elevations in LDH may occur as many as 4 months before
changes in pfHb with clinical signs of hemolysis11. Guidelines from the
International Society for Heart and Lung Transplantation recommend to follow
biologic markers for hemolysis as a sign of thrombosis13. Akin et al. report a
sensitivity and specificity of LDH greater than three times the upper limit of normal
of 88% and 97%, respectively12. Similarly, Uriel et al. found that an LDH greater
than four times the upper limit of normal was 100% sensitive and 92.5% specific
for pump thrombosis at the time of diagnosis9. Of note, a study by Shah, et al
found that LDH levels associated with centrifugal (e.g. Heartware) LVADs are, in
general, lower than with axial flow (e.g. HeartMate II) LVADs. Not only did they
show LDH was more sensitive for pump thrombosis than pfHb, but extrapolation of
their data indicated that a lower threshold of LDH elevation may be required to
evaluate for pump thrombosis in Heartware LVADs14. Thus, LDH has been shown
to be an important adjunct in early diagnosis of LVAD-related thrombosis.
After an extensive literature review, this is the first case report we have come
across where there was no clear evidence of hemolysis appreciated prior to
confirmed pump thrombosis. Our patient, in fact, had an LDH and plasma free
hemoglobin within the normal limits of our laboratory values. He did have
evidence of pump failure given minimal flow upon LVAD interrogation, as well as
clinical signs of heart failure evidenced by worsening pulmonary and peripheral
edema, anuria, and worsening intracardiac hemodynamics. Given such a clear
clinical picture of LVAD pump failure, our index of suspicion for pump thrombosis
remained high. Ultimately, the fact that this patient had normal hemolysis
biomarkers in the setting of significant pump thrombosis suggests that we must
question the sensitivity of LDH as an early detector of this significant complication.
Hemolysis occurs due to mechanical damage to red blood cells (RBCs). Turbulent
flow and high shear stress on RBCs, especially during periods of hemodynamic
instability, contribute to hemolysis. Heat generation as well as the rough, textured
surfaces of the device may also play a role5,7-8. All of these factors rely on blood
flow through the pump in order for mechanical damage to RBCs to occur. In our
patient, the complete occlusion of the pump meant he had no blood flow through
his device and, therefore, no cellular damage or hemolysis. While he did have a
pump thrombosis leading to pump failure, hemolysis biomarkers were not helpful
in the diagnosis. The diagnosis of pump thrombosis can be challenging, but in a
patient with pump failure and clinical evidence of worsened heart failure it must
remain on the differential.
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